Article
<i>BRCA2</i> abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
2018-12-10
Abstract excerpt
Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, BRCA2 inactivation in tumors is associated with uncontrolled cell proliferation. We set out to investigate this conundrum by exploring modalities of cell adaptation to loss of BRCA2 and focused on genome-wide transcriptome alterations. Hu...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c34cecfc-2672-518a-9172-da06e9d7ce3c
- DOI
- 10.1101/490268
